Abbott Laboratories ABT
NYSE · Healthcare · Medical - Devices
$103.00
Close on Fri, 20 Nov 2026 · market value $178B
What the price is betting on
Below its recordAt $103, the price assumes revenue grows about 6.1% a year for five years, from $48.2B to about $62B by FY2030. That is less than what analysts expect for the next two years and about the same as the company's own last three years.
Revenue growth a year. The price figure comes from a reverse DCF at a 7.5% discount rate.
Track it and Parra checks each report against the path, and tells you when revenue falls behind it.
Own more than ABT? Check up to 5 of your stocks at once, free, no account.
Both sides
Three stories, three values
Bear
$95
Base
$113
Bull
$135
Today $103
- Bear $95. Cash flow grows 5% a year for the next 5 years, slower than expected, then slows to long-run growth.
- Base $113. Cash flow grows 8% a year for the next 5 years, as analysts expect, then slows to long-run growth.
- Bull $135. Cash flow grows 11% a year for the next 5 years, faster than expected, then slows to long-run growth.
Stories set by rules from the company’s record.
Checkpoints
The revenue the price needs
- YearNeedsAnalysts expect
- FY2026$49B$50B, on the path
- FY2027$51.9B$53.6B, on the path
- FY2028$55.1B$57.1B, on the path
- FY2029$58.5B$61.4B, on the path
- FY2030$62B$65.8B, on the path
Each year's revenue at 6.1% growth from $48.2B in the 12 months to September 2026.
At a glance
Healthcare · Medical - Devices · listed on NYSE
- Revenue, FY2025
- $44.3B
- Growth, 3 years a year
- 6.9%
- Cash margin
- 17%
- Net debt
- $6.1B
- Shares, 3-year change
- −1%
- Dividend yield
- 2.3%
What other healthcare prices are betting on
Figures from company filings and end-of-day market data, as of the close on Fri, 20 Nov 2026; updated every trading day. This page shows what today's price assumes, not whether to buy or sell. Not investment advice.